However, a scarcity of current literature regarding the effects of SGLT2 inhibitors on epigenetic mechanisms shows the need for further research regarding the effects of SGLT2 inhibitors on the epigenetics of NAFLD. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.